Novartis is buying a U.K. cancer drug startup for up to $1.5 billion
The Swiss drugmaker will pay $1.1 billion upfront and up to $400 million in milestones to gain a novel antibody-drug conjugate payload platform
Overview
The Swiss drugmaker will pay $1.1 billion upfront and up to $400 million in milestones to gain a novel antibody-drug conjugate payload platform
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
